Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | KIF11 | P52732 | 6/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147712 | 0.89 | KCNN4 (0.52) | TP53KIF11TAAR1SLC6A2KMT2A | |
| Iodide SCHEMBL28805520 | 0.86 | KCNN4 (0.50) | TP53KIF11TAAR1SLC6A2KMT2A | |
| Hydrochloric Acid SCHEMBL317557 | 0.86 | KCNN4 (0.50) | TP53KIF11TAAR1SLC6A2KMT2A | |
| Bromide SCHEMBL28680752 | 0.86 | KCNN4 (0.50) | TP53KIF11TAAR1SLC6A2KMT2A | |
| Ethylbenzene SCHEMBL27403156 | 0.79 | TP53 (0.78) | TP53KIF11TAAR1SLC6A2MEN1 | |
| SCHEMBL6307824 | 0.78 | MAPT (0.44) | KIF11TAAR1SLC6A2KCNN4CYP1A2 | |
| Ethylbenzene SCHEMBL9618498 | 0.78 | TP53 (0.88) | TP53KIF11TAAR1SLC6A2CYP1A2 | |
| Ethylbenzene SCHEMBL1312847 | 0.78 | TP53 (0.88) | TP53KIF11TAAR1SLC6A2CYP1A2 | |
| Ethylbenzene SCHEMBL1330604 | 0.78 | — | — | |
| Ethylbenzene SCHEMBL7458207 | 0.78 | TP53 (1.00) | TP53TAAR1CYP1A2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20060229470-A1 | Calcium receptor-active molecules | NPS PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1366764-B1 | Method of screening for calcium receptor-active molecules | BRIGHAM & WOMENS HOSPITAL (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1632470-A2 | Calcium receptor active molecules | NPS PHARMACEUTICALS, INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1281702-B1 | Calcium receptor active molecules | NPS PHARMA INC (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1296142-B1 | Screening method for calcium receptor active molecules | NPS PHARMA INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1466888-A1 | Calcium receptor-active arylalkyl amines | NPS PHARMACEUTICALS, INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-0637237-B1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | BRIGHAM & WOMENS HOSPITAL (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-0724561-B1 | CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES | NPS PHARMA INC (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1366764-A1 | Method of screening for calcium receptor-active molecules | The Brigham & Women's Hospital, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-5858684-A | CONTACTING RECOMBINANT CELL WITH TEST COMPOUND WHICH IS NOT VERAPAMIL OR GALLOPAMIL, DETERMINING ABILITY OF COMPOUND TO AFFECT ACTIVITIES OF INORGANIC ION RECEPTOR; DETERMINATION OF AGONIST AND ANTAGONIST DRUGS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5763569-A | POLYPEPTIDES AS CALCIUM RECEPTORS TO GENERATE ANTIBODIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC (US) | 1998-06-09 | — | — | US | disclosed |
| US-5688938-A | Calcium receptor-active molecules | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0724561-A1 | CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES | NPS PHARMACEUTICALS, INC. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1996005818-A1 | METHODS AND COMPOUNDS ACTIVE AT METABOTROPIC GLUTAMATE RECEPTORS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0657029-A4 | CALCIUM RECEPTOR ACTIVE MOLECULES. | NPS PHARMA INC (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0657029-A1 | CALCIUM RECEPTOR ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1995011221-A1 | CALCIUM RECEPTOR-ACTIVE ARYLALKYL AMINES | NPS PHARMACEUTICALS, INC. (US) | 1995-04-27 | — | — | WO | disclosed |
| EP-0637237-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1993004373-A1 | CALCIUM RECEPTOR ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229470-A1 | Calcium receptor-active molecules | CASR, CALCR, ORAI1 | TP53 1925/4885KIF11 4670/4885TAAR1 938/4885 |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | CASR, CALCR, ORAI1 | TP53 1925/4885KIF11 4670/4885TAAR1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.